0001631246-15-000001.txt : 20150123 0001631246-15-000001.hdr.sgml : 20150123 20150123150144 ACCESSION NUMBER: 0001631246-15-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20150123 DATE AS OF CHANGE: 20150123 EFFECTIVENESS DATE: 20150123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspyrian Therapeutics, Inc. CENTRAL INDEX KEY: 0001595215 IRS NUMBER: 272624716 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-232786 FILM NUMBER: 15545126 BUSINESS ADDRESS: STREET 1: 11189 SORRENTO VALLEY RD. STE 104 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-784-9098 MAIL ADDRESS: STREET 1: 11189 SORRENTO VALLEY RD. STE 104 CITY: SAN DIEGO STATE: CA ZIP: 92121 D 1 primary_doc.xml X0707 D LIVE 0001595215 Aspyrian Therapeutics, Inc. 11189 SORRENTO VALLEY RD. STE 104 SAN DIEGO CA CALIFORNIA 92121 858-784-9098 DELAWARE None None Corporation true 2010 Scott Salka 11189 Sorrento Valley Rd, Suite 104 San Diego CA CALIFORNIA 92121 Executive Officer Director Miguel Garcia-Guzman 11189 Sorrento Valley Rd, Suite 104 San Diego CA CALIFORNIA 92121 Executive Officer Director Biotechnology Decline to Disclose 06b false 2014-12-05 false true true true false 0 8455175 8455175 0 Total amount sold includes $6,480,000 of securities issued upon conversion of the principal and interest outstanding under a convertible promissory note. Also includes $176 of Common Stock sold pursuant to a Common Stock Purchase Agreement. false 8 0 0 0 false Aspyrian Therapeutics, Inc. /s/ Scott Salka Scott Salka CEO 2015-01-23